AbCellera Biologics (AbCellera Biologics) Beginning Cash Position : $199.71 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is AbCellera Biologics Beginning Cash Position?

AbCellera Biologics's Beginning Cash Position for the quarter that ended in Dec. 2023 was $199.71 Mil.

AbCellera Biologics's quarterly Beginning Cash Position declined from Jun. 2023 ($220.31 Mil) to Sep. 2023 ($207.04 Mil) and declined from Sep. 2023 ($207.04 Mil) to Dec. 2023 ($199.71 Mil).

AbCellera Biologics's annual Beginning Cash Position declined from Dec. 2021 ($594.12 Mil) to Dec. 2022 ($501.14 Mil) and declined from Dec. 2022 ($501.14 Mil) to Dec. 2023 ($414.65 Mil).

AbCellera Biologics Beginning Cash Position Historical Data

The historical data trend for AbCellera Biologics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Beginning Cash Position Chart

AbCellera Biologics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

10.44

7.55

594.12

501.14

414.65

AbCellera Biologics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Beginning Cash Position	Get a 7-Day Free Trial														400.09	414.65	220.31	207.04	199.71

AbCellera Biologics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

AbCellera Biologics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

AbCellera Biologics (AbCellera Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (NAS:ABCL) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

8QQ:Germany

Address

2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1

Website

https://www.abcellera.com

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Executives

John S. Montalbano	director	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Michael R Hayden	director	C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Veronique Lecault	director, officer: Chief Operating Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Thermopylae Holdings Ltd.	10 percent owner	2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Booth	officer: Chief Financial Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Lo	director	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
John Hamer	director, 10 percent owner	PO BOX 14528, RESEARCH TRIANGLE PARK NC 27709-4528
Ester Falconer	officer: Chief Technology Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Hansen Carl L. G.	director, 10 percent owner, officer: Chief Executive Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Tryn Stimart	officer: Chief Legal Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Peter Thiel	director	9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Dcvc Bio, L.p.	10 percent owner	317 UNIVERSITY AVENUE, SUITE 200, PALO ALTO CA 94301
Dcvc Bio Gp, Llc	10 percent owner	270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Zachary Bogue	10 percent owner	270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Matthew Ocko	10 percent owner	270 UNIVERSITY AVENUE, PALO ALTO CA 94301